Expert Insights on Managing IDH- and FLT3-Mutant AML: Bringing Precision Medicine to Daily Practice

Join us for this live CME activity focused on the role of IDH and FLT3 mutations in acute myeloid leukemia (AML). Discover how these genetic alterations impact prognosis and shape targeted treatment strategies. Our expert faculty will present key clinical evidence for IDH1/2 inhibitors and FLT3-directed therapies, while addressing treatment sequencing and the integration of emerging options into practice. The discussion will also highlight precision medicine approaches and evidence-based strategies for managing patients with AML with actionable mutations.

Registration Fee - Complimentary Registration*

*Registration is required to attend this course and is limited to 75 learners.

1. Click the Register button at the top of this page to complete your course registration.

2. After registering, you will receive a Zoom registration link to complete your virtual meeting registration and obtain access to the session.

3. Use the same name and email address for both registrations to ensure accurate attendance tracking and CME credit reporting.

Virtual Meeting and Data Sharing Notice
This virtual course will be hosted by Paradigm Medical Communications, LLC, through Zoom.
Your name and email address will be shared with Paradigm Medical Communications, LLC, solely to facilitate virtual meeting access and coordinate your participation.

Course Recording
All registrants (virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the course. 

The recorded sessions are not approved for Continuing Education (CE) credit.

Questions?
If you have questions about enrollment, please email [email protected] or call (310) 794-2620.

1. Assess the role of molecular testing in AML, including the types of tests available, as well as the pros and cons of testing.
2. Apply the latest evidence-based guidelines to the selection of an appropriate treatment for patients with IDH- or FLT3-mutant AML, based on mutation type, clinical factors, and the characteristics of available treatment options.

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The California State Board of Registered Nursing accepts courses approved by the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies. 

Educational Collaboration
This activity was developed in collaboration with Paradigm Medical Communications, LLC.

Mitigation of Relevant Financial Relationships

The Accreditation Council for Continuing Medical Education (ACCME), Standards for Integrity and Independence mandates that the accreditation manages all identified relevant financial relationship(s) before the program and adequately discloses relationships to learners. The David Geffen School of Medicine at UCLA adheres to the ACCME Standards for Integrity and Independence in accredited continuing education.

The individuals below have been identified as having a position to influence the content of this educational activity. As such, they have disclosed the absence or presence of a relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for these individuals have been mitigated.

Thursday, November 19, 2026